Mark Schuuring (@mjschuuring) header
Mark Schuuring (@mjschuuring) profile picture

Cardiologist (M.D Ph.D. FESC FEACVI FHFA) at MST @ziekenhuisMST #CVImaging #HeartFailure and Researcher at University of Twente @UTwente #digital #eHealth #AI

The Netherlands
Joined November 2009
Photo by Mark Schuuring (@mjschuuring)Photo by Mark Schuuring (@mjschuuring)Photo by Mark Schuuring (@mjschuuring)Photo by Mark Schuuring (@mjschuuring)Photo by Mark Schuuring (@mjschuuring)Photo by Mark Schuuring (@mjschuuring)Photo by Mark Schuuring (@mjschuuring)Photo by Mark Schuuring (@mjschuuring)Photo by Mark Schuuring (@mjschuuring)Photo by Mark Schuuring (@mjschuuring)
Challenges of aortic valve stenosis #VHD scenarios: how to get the diagnosis right with @EACVIPresident 🗓️Thursday, 16 October 2025, ⏲️ 18:00 to 19:00 CEST #Webinar Organiser: European Association of Cardiovascular Imaging (EACVI) Register now: 👉esc365.escardio.org/event/20…
12
23
2,237
🔥 New in @NatureMedicine How do you communicate lifetime benefits expected with HFpEF therapies? New data from 3 RCTs (#DELIVER #FINEARTS #PARAGON) estimate up to *5 years* of event-free survival w combination Rx #GDMT for HFpEF has finally arrived! 🔗nature.com/articles/s41591-0…
8
140
6
342
38,012
Development of an Innovative Pipeline With Fusion, Digital Planning, and Three‐Dimensional Printing to Improve Mitral Valve Interventional Care - Man - 2025 - Echocardiography - Wiley Online Library onlinelibrary.wiley.com/doi/…
1
2
1
4
1,240
📢 Results of our EASY-STOP study now presented #LBCT at #HeartFailure2025! A thread 🧵 1/ 🚀 First study to evaluate home-based #UNa using a POC sensor to guide loop diuretic downtitration in chronic #HeartFailure patients. #Cardiology #FOAMed
1
16
2
36
3,355
🚨 Excited to share our work on #AI #DASSi phenotyping of #AS on 2D #EchoFirst: a low-cost surrogate for multimodality imaging in AS trials A fun collaboration between @cards_lab @rohan_khera & @EdinburghUni (Marc Dweck, @neiljcraig et al) 🔗 Preprint + 🧵below #ACC25
1
16
50
3,193
For all the passionate professionals for cardiovascular imaging, this is your opportunity to mingle with, to network with and to learn from a large community with expertise on 4 modalities. Take advantage and join us! escardio.org/Congresses-Even… @iCorGTrias @imagen_sec
Join Us at the #EACVI 2025 Conference in Vienna! 📅 December 11-13, 2025 📍 Vienna, Austria Experience the future of cardiovascular imaging as #EuroEcho #ICNCCT & #EuroCMR come together under one roof at the #EACVI 2025 Conference! 🔹 Cutting-edge research 🔹 Expert-led sessions 🔹 Multimodality imaging insights 🔹 Networking with global leaders Don’t miss this unparalleled opportunity to advance your knowledge and connect with the best in the field! escardio.org/Congresses-Even… @VDelgadoGarcia @s_e_petersen @denisamuraru @NAjmoneMarsan @anatimoteo46040 @LunaGargani @PezelT @carpenter_jp @rmanka_ @Sarah_Moharem
24
1
63
4,457
Using #ArtificialIntelligence to calculate the heart’s biological age through #ECG data predicts increased risk of mortality and #cardiovascular events 👇 #AI #HeartHealth #EHRA2025 #EHRA_ESC
2
46
4
127
13,581
Mark Schuuring retweeted
Would you discharge an eligible patient with HFrEF w/o one or more disease-modifying, life-saving medications? How about if you knew the odds are 7-15 fold against them ever being initiated as an outpatient? How about if you were contributing to 100K preventable ☠️s per year?
2
17
34
3,052
Mark Schuuring retweeted
What is the likelihood that this RCT will meet its primary endpoint? A Digital Platform to Optimize Guideline Directed Heart Failure Therapy: Rationale and Design of the AIM-POWER Trial - Journal of Cardiac Failure onlinejcf.com/article/S1071-… @JCardFail @robmentz @texhern @HFSA
6
13
1,316
Mark Schuuring retweeted
✅ When RCT protocol directed, a large proportion of patients with HFrEF are treated with quadruple GDMT ❌ In clinical practice, when left to clinician discretion, it is < 1 in 10 of patients eligible that are actually treated, even in settings with no cost/access barriers
2
26
1
46
7,915
Mark Schuuring retweeted
HFmrEF/HFpEF can’t wait Rx the 3 🏛️ SGLTi + nsMRA + GLP-1 RA (if obesity) The optimal strategy is simultaneous or rapid sequence initiation to all eligible patients, without delay @gcfmd @JavedButler1 @DCRINews @JAMACardio jamanetwork.com/journals/jam……
57
2
144
10,038
The role of multi-modality imaging for the assessment of left atrium and #LAA: a clinical consensus statement of the @EACVIPresident & @EHRAPresident of @escardio by @EHJCVIEiC @leylaelifsade et al. ☑️shorturl.at/ukSeX @denisamuraru @EHJIMPEiC @JGrapsa @BakhshiHooman
1
24
58
4,280
Patients with suspected heart failure and elevated NT-proBNP in outpatient care had high mortality and morbidity in the weeks after presentation. Read the results of the REVOLUTION HF study just published in #EHJ 👉 bit.ly/3CSmnns @RoccoMontone @ehj_ed #heartfailure
2
44
5
126
13,204
#Initiation of sac/val in pts with #denovo #HFrEF improves NPs & outcomes. However, RCTs were of modest size. In @ESC_Journals, #RWE from >3200 #Medicare enrollees assessed sac/val in this pop. finding similar efficacy to #RCTs. Early #ImpSci leads to sustained⏬clinical events.
3
8
33
3,142
Mark Schuuring retweeted
When clinical trial protocol directed, a large proportion of of patients with HFrEF are treated with quadruple GDMT In actual practice, when left to clinical discretion, it is < 1 in 10 of patient eligible that are actually treated, even in settings with no cost/access barriers
Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial The VICTOR trial enrolled the most optimally treated population in a phase III heart failure trial onlinelibrary.wiley.com/doi/…
1
12
30
4,103
You can predict 30d ☠️ following #HF #hospitalization w just 2 variables - Length of 🏥stay - n of ED visits in prior 6 mo In an external validation study (n 1206) our simple #LE index performed better than complex #risk scores Each point: ~2x odds of☠️ onlinelibrary.wiley.com/doi/…
6
30
1
68
8,657